Panel Details
Topic:
Date:
Time:
A replay of the panel discussion will also be available for 30 days on Aadi's website within the News/Events & Presentations section.
About
Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. In
Based on data from the AMPECT trial with FYARRO and following discussions with the FDA about other emerging data with FYARRO, Aadi has initiated PRECISION-1, a tumor-agnostic registrational trial in mTOR inhibitor-naive solid tumors harboring TSC1 or TSC2 inactivating alterations. Aadi also has ongoing studies to evaluate dosing of FYARRO in combination regimens. More information on Aadi's development pipeline is available on the Aadi website at www.aadibio.com.
Contact:
Investors
E: ikoffler@lifesciadvisors.com
Media
E: darren@lifescicomms.com
(C) 2022 Electronic News Publishing, source